Market data

Select a section

Arix Bioscience

(ARIX)
Sector: Investment Banking and Brokerage Services
142.00p
0.00p 0.00
Last updated: 16:34:56

Company News Headlines

Date Time Headline Source
07/02/2024 11:30 Transaction Update EQS Group
29/01/2024 12:15 Results of First General Meeting EQS Group
24/01/2024 17:30 Holding(s) in Company EQS Group
24/01/2024 17:30 Holding(s) in Company EQS Group
23/01/2024 07:00 Update on the Scheme and Publication of Notice of Second General Meeting EQS Group
22/01/2024 07:00 Update on the Scheme and Resignation of Directors EQS Group
19/01/2024 07:01 Financial update on Harpoon Therapeutics acquisition by Merck (MSD) EQS Group
19/01/2024 07:00 Unaudited NAV for December 2023 EQS Group
08/01/2024 17:15 Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD) EQS Group
05/01/2024 07:00 Publication of Circular and RTW Bio Prospectus EQS Group
04/01/2024 17:30 Holding(s) in Company EQS Group
22/12/2023 11:00 Update regarding timing of Proposed Scheme of Reconstruction EQS Group
13/12/2023 07:00 Unaudited NAV for November 2023 EQS Group
08/12/2023 07:00 Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial EQS Group
13/11/2023 16:00 Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock EQS Group
10/11/2023 08:00 Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock EQS Group
10/11/2023 07:00 PDMR Notification & Director Shareholding EQS Group
08/11/2023 07:05 Unaudited NAV for October 2023 EQS Group
03/11/2023 16:30 PDMR Notification & Director Shareholding EQS Group
02/11/2023 18:20 PDMR Notification & Director Shareholding EQS Group
01/11/2023 16:30 Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102 EQS Group
01/11/2023 07:06 RTW Biotech to acquire Arix Bioscience's assets RNS
24/10/2023 07:00 Portfolio company Harpoon Therapeutics announces up to $150 million private placement EQS Group
06/10/2023 07:00 Unaudited NAV for September 2023 EQS Group
27/09/2023 07:01 Interim Results for the Six Months Ended 30 June 2023 EQS Group
27/09/2023 07:00 Board Change EQS Group
14/09/2023 07:01 Notice of Results and Investor Presentation EQS Group
14/09/2023 07:00 Unaudited NAV for August 2023 EQS Group
07/08/2023 07:00 Unaudited NAV for July 2023 EQS Group
17/07/2023 15:00 Holding(s) in Company EQS Group
13/07/2023 07:01 Arix Announces Strategic Review EQS Group
13/07/2023 07:00 Unaudited NAV for June 2023 EQS Group
23/06/2023 14:04 Portfolio company Disc Medicine raises $157.8 million in public offering EQS Group
09/06/2023 07:00 Unaudited NAV for May 2023 EQS Group
09/06/2023 14:53 Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA EQS Group
31/05/2023 11:51 Director/PDMR Shareholding RNS
24/05/2023 07:00 Correction: Result of Annual General Meeting EQS Group
23/05/2023 16:30 Result of Annual General Meeting EQS Group
16/05/2023 16:36 Portfolio company Ensoma announces closing of Series B Extension EQS Group
12/05/2023 07:00 Unaudited NAV for April 2023 EQS Group
05/05/2023 16:30 Total Voting Rights RNS
04/05/2023 17:02 Director/PDMR Shareholding RNS
04/05/2023 12:15 Director/PDMR Shareholding RNS
02/05/2023 15:52 Director/PDMR Shareholding RNS
27/04/2023 07:00 Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune EQS Group
25/04/2023 07:03 Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM EQS Group
19/04/2023 13:30 Full Year results now to be released on 25 April 2023 EQS Group
17/04/2023 07:00 Unaudited NAV for March 2023 EQS Group
14/04/2023 12:00 Notice of Results and Investor Presentation EQS Group
28/03/2023 07:00 Portfolio company Harpoon Therapeutics announces closing of $25 million private placement EQS Group

Market data

Select a section